The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan.

Jeng-Shiun DuYi-Chun KuoHon-Yi ShiMing-Chung WangLi-Ying WangTzer-Ming ChuangYa-Lun KeTsung-Jang YehYu-Ching GauHui-Ching WangShih-Feng ChoSamuel Yien HsiaoYi-Chang LiuChin-Mu HsuHui-Hua Hsiao

Published in: Journal of personalized medicine (2022)

The study demonstrated the greater clinical benefit and cost-effectiveness of VTD compared to VMP therapy in transplant-ineligible, newly diagnosed myeloma patients.

Keyphrases

newly diagnosed
multiple myeloma
high dose
low dose
stem cells
prognostic factors
patient reported outcomes
patient reported